Conditions: Venous Thrombosis
Keywords: Bleeding rates Prophylaxis for deep vein thrombosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1
Healthy volunteers: no

Brief summary:
A total of 50 patients \>40 yrs of age with an expected hospital stay in the Medical Intensive Care or Regional Heart Unit at LVH Muhlenberg of 6 days or longer will be enrolled. The patient and study team will be blinded to which drug they are receiving (either Arixtra or Lovenox). Subjects will be examined for any bleeding complications. Subjects will receive drug for a total of 6-14 days while in the hospital. A follow up phone call will be performed by the study team approximately 30 days after discharge from the hospital.

Detailed description:
A total of 50 patients will be enrolled in this double-blinded, randomized, controlled trial. Inclusion criteria: subjects\>40 yrs of age with an expected hospital stay in the Medical Intensive Care or Regional Heart Unit at LVH Muhlenberg of 6 days or longer (4 days bedridden) will be enrolled. Total drug treatment will be 6-14 days while in the hospital. A follow up phone call will be performed by the study team approximately 30 days after hospital discharge. Primary endpoint: bleeding rate (minor vs major) between study days 1-14. Secondary endpoint: DVT study days 1-14 (confirmed with LE duplex ultrasonogram).

Arms:
arm 1: Arixtra (Fondaparinox) 2.5 mg SC Daily arm 2: Lovenox 40mg SC Daily

Interventions: intervention 1: Arixtra (Fondaparinox) 2.5 mg SC Daily intervention 2: Lovenox 40mg SC Daily
Intervention descriptions: intervention 1: Patients will be randomized to receive Arixtra 2.5mg once a day if randomized to this arm intervention 2: Patients will be randomized to receive Lovenox 40mg SC Daily if randomized to this arm

Protocol document: